Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Orexo to present clinical data for OX640 at the EAACI Congress | 178 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
06.05. | Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements | 1 | Investing.com | ||
06.05. | Orexo AB: Orexo Q1 2025 Interim Report | 79 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
10.04. | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 305 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 84 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
10.01. | Orexo Announces Positive Data From Clinical Study Of OX640 Evaluating Allergic Reactions | 1 | RTTNews | ||
OREXO Aktie jetzt für 0€ handeln | |||||
10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 391 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
18.12.24 | Abera and Orexo partner for vaccine powder formulations | 2 | Pharmaceutical Technology | ||
17.12.24 | Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology | 2 | Seeking Alpha | ||
17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 452 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 275 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 310 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
24.10.24 | Orexo Interim Report Q3 2024 | 459 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
04.10.24 | Orexo's Nomination Committee for the Annual General Meeting 2025 | 318 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen | |
03.09.24 | Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024 | 317 | PR Newswire | UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference... ► Artikel lesen | |
17.07.24 | Orexo Q2 2024 Interim Report | 417 | PR Newswire | UPPSALA, Sweden, July 17, 2024 /PRNewswire/ --
Making progress, while the OX124 review time extended
Q2 2024 highlights
Total net revenues of SEK 154.0 m (157.7)EBITDA of SEK... ► Artikel lesen | |
16.07.24 | Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose | 413 | PR Newswire | UPPSALA, Sweden, July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food... ► Artikel lesen | |
10.07.24 | Orexo AB's sustainability work ranked among top 5% by EcoVadis | 467 | PR Newswire | UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world's most trusted... ► Artikel lesen | |
08.07.24 | Orexo: invitation to presentation of the Q2 2024 Interim Report | 413 | PR Newswire | UPPSALA, Sweden, July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 5,030 | +0,20 % | Aurora Cannabis Inc (3): Aurora Cannabis launches IndiMed Tempo 22 | ||
ABBVIE | 166,40 | -0,12 % | AbbVie continues gains for seven straight sessions | ||
TILRAY BRANDS | 0,357 | +0,11 % | Tilray Brands Inc: Tilray Brands to be deleted from S&P/TSX Composite | ||
BRISTOL-MYERS SQUIBB | 42,300 | -0,39 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
TEVA | 15,250 | -2,24 % | Teva Pharmaceutical: Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building | NORTHAMPTON, MA / ACCESS Newswire / June 6, 2025 / Teva Pharmaceutical:At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of patients... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 395,50 | +0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | - Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with... ► Artikel lesen | |
CRONOS GROUP | 1,728 | -0,80 % | Cronos Group Inc.: Cronos Group Reports 2025 First Quarter Results | Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS® retained its position as the number one cannabis brand in... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 7,718 | -1,56 % | EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration | - Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest - - LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of... ► Artikel lesen | |
BAUSCH HEALTH | 4,220 | +1,15 % | Bausch Health Companies Inc: Bausch Health Announces 2025 Annual Meeting of Shareholder Results | LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 67,46 | -0,82 % | Is Edwards Lifesciences Stock Underperforming the Dow? | ||
QUANTUM BIOPHARMA | 12,500 | -8,09 % | Quantum BioPharma Clarifies It Has Not Changed Its Name | TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative... ► Artikel lesen | |
BIONANO GENOMICS | 3,730 | +1,36 % | Bionano Genomics: Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 5,250 | -0,94 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four... ► Artikel lesen | |
AMARIN | 10,600 | -5,36 % | XFRA EH3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
OPKO HEALTH | 1,200 | +0,22 % | Opko Health auf Jefferies-Konferenz: Strategische Umstrukturierung und Wachstumspläne |